Undoubtedly, ChREBP has a central and pleiotropic role in metabolic regulation, which, in turn, means that its study as a therapeutic target in diseases such as T2DM or fatty liver may involve adverse effects. Here, MLXIPL is linked to type 2 diabetes mellitus.